Algert Global LLC Invests $136,000 in Enhabit, Inc. (NYSE:EHAB)

Algert Global LLC bought a new position in Enhabit, Inc. (NYSE:EHAB) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 15,264 shares of the company’s stock, valued at approximately $136,000.

Other hedge funds have also modified their holdings of the company. Empowered Funds LLC boosted its position in shares of Enhabit by 87.7% in the first quarter. Empowered Funds LLC now owns 147,594 shares of the company’s stock worth $1,719,000 after acquiring an additional 68,966 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Enhabit by 39.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 340,412 shares of the company’s stock worth $3,861,000 after acquiring an additional 95,488 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Enhabit in the second quarter worth approximately $955,000. Marshall Wace LLP acquired a new stake in shares of Enhabit in the second quarter worth approximately $1,941,000. Finally, Orion Portfolio Solutions LLC boosted its position in shares of Enhabit by 72.5% in the first quarter. Orion Portfolio Solutions LLC now owns 96,833 shares of the company’s stock worth $1,128,000 after acquiring an additional 40,684 shares during the last quarter.

Enhabit Stock Performance

EHAB stock opened at $7.20 on Friday. The company has a market capitalization of $362.02 million, a P/E ratio of -42.35 and a beta of 1.81. The company has a 50-day simple moving average of $8.07 and a 200 day simple moving average of $9.07. Enhabit, Inc. has a fifty-two week low of $6.94 and a fifty-two week high of $11.74. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.73.

Enhabit (NYSE:EHAB) last issued its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. The company had revenue of $260.60 million for the quarter, compared to the consensus estimate of $265.99 million. Enhabit had a positive return on equity of 1.61% and a negative net margin of 0.84%. During the same quarter in the prior year, the company earned $0.04 EPS. Sell-side analysts predict that Enhabit, Inc. will post 0.26 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey Bolton purchased 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average price of $8.01 per share, for a total transaction of $40,050.00. Following the completion of the acquisition, the director now directly owns 78,877 shares in the company, valued at approximately $631,804.77. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.90% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Bank of America reduced their price target on shares of Enhabit from $9.00 to $8.00 and set an “underperform” rating on the stock in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.35.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.